Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb

Clinical Immunology

Volumn 125, Issue 1, 2007, Pages 76-87

  Li, Betty ^a   Lin, Jianmin ^a   VanRoey, Melinda ^a   Jure Kunkel, Maria ^b   Jooss, Karin ^a  

^a CELL GENESYS INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anti 4 1BB; CD137; GM CSF; Immunotherapy; T cell response; TIL infiltration; Tumor rejection

Indexed keywords

CD137 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4 1BB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER MODEL; CANCER PATIENT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 34548512807     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.07.005     Document Type: Article

References (40)

1. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23 (2005) 23-68
2. Shuford W.W., Klussman K., Tritchler D.D., Loo D.T., Chalupny J., Siadak A.W., Brown T.J., Emswiler J., Raecho H., Larsen C.P., Pearson T.C., Ledbetter J.A., Aruffo A., and Mittler R.S. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186 (1997) 47-55
3. Takahashi C., Mittler R.S., and Vella A.T. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162 (1999) 5037-5040
4. Cannons J.L., Lau P., Ghumman B., DeBenedette M.A., Yagita H., Okumura K., and Watts T.H. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 167 (2001) 1313-1324
5. Melero I., Shuford W.W., Newby S.A., Aruffo A., Ledbetter J.A., Hellstrom K.E., Mittler R.S., and Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3 (1997) 682-685
6. Melero I., Bach N., Hellstrom K.E., Aruffo A., Mittler R.S., and Chen L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol. 28 (1998) 1116-1121
7. Nam K.O., Kang H., Shin S.M., Cho K.H., Kwon B., Kwon B.S., Kim S.J., and Lee H.W. Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes. J. Immunol. 174 (2005) 1898-1905
8. Pollok K.E., Kim Y.J., Zhou Z., Hurtado J., Kim K.K., Pickard R.T., and Kwon B.S. Inducible T cell antigen 4-1BB. Analysis of expression and function. J. Immunol. 150 (1993) 771-781
9. Ju S.A., Lee S.C., Kwon T.H., Heo S.K., Park S.M., Paek H.N., Suh J.H., Cho H.R., Kwon B., Kwon B.S., and Kim B.S. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol. Cell Biol. 83 (2005) 344-351
10. Myers L., Lee S.W., Rossi R.J., Lefrancois L., Kwon B.S., Mittler R.S., Croft M., and Vella A.T. Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int. Immunol. 18 (2006) 325-333
11. Pulle G., Vidric M., and Watts T.H. IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J. Immunol. 176 (2006) 2739-2748
12. Jaffee E.M., Hruban R.H., Biedrzycki B., Laheru D., Schepers K., Sauter P.R., Goemann M., Coleman J., Grochow L., Donehower R.C., Lillemoe K.D., O'Reilly S., Abrams R.A., Pardoll D.M., Cameron J.L., and Yeo C.J. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19 (2001) 145-156
13. Simons J.W., Mikhak B., Chang J.F., DeMarzo A.M., Carducci M.A., Lim M., Weber C.E., Baccala A.A., Goemann M.A., Clift S.M., Ando D.G., Levitsky H.I., Cohen L.K., Sanda M.G., Mulligan R.C., Partin A.W., Carter H.B., Piantadosi S., Marshall F.F., and Nelson W.G. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59 (1999) 5160-5168
14. Nemunaitis J., Sterman D., Jablons D., Smith II J.W., Fox B., Maples P., Hamilton S., Borellini F., Lin A., Morali S., and Hege K. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl. Cancer Inst. 96 (2004) 326-331
15. Salgia R., Lynch T., Skarin A., Lucca J., Lynch C., Jung K., Hodi F.S., Jaklitsch M., Mentzer S., Swanson S., Lukanich J., Bueno R., Wain J., Mathisen D., Wright C., Fidias P., Donahue D., Clift S., Hardy S., Neuberg D., Mulligan R., Webb I., Sugarbaker D., Mihm M., and Dranoff G. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21 (2003) 624-630
16. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., and Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 3539-3543
17. Soiffer R., Hodi F.S., Haluska F., Jung K., Gillessen S., Singer S., Tanabe K., Duda R., Mentzer S., Jaklitsch M., Bueno R., Clift S., Hardy S., Neuberg D., Mulligan R., Webb I., Mihm M., and Dranoff G. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. 21 (2003) 3343-3350
18. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., and Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188 (1998) 2357-2368
19. van Elsas A., Sutmuller R.P., Hurwitz A.A., Ziskin J., Villasenor J., Medema J.P., Overwijk W.W., Restifo N.P., Melief C.J., Offringa R., and Allison J.P. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194 (2001) 481-489
20. Simmons A.D., Li B., Gonzalez-Edick M., Lin C., Moskalenko M., Du T., Creson J., VanRoey M.J., and Jooss K. GM-CSF-secreting cancer immunotherapies:preclinical analysis of the mechanism of action. Cancer Immunol. Immunother. 56 10 (2007) 1653-1665
21. Fernandes D.M., Vidard L., and Rock K.L. Characterization of MHC class II-presented peptides generated from an antigen targeted to different endocytic compartments. Eur. J. Immunol. 30 (2000) 2333-2343
22. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., and Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72 (1998) 8463-8471
23. Cheuk A.T., Mufti G.J., and Guinn B.A. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther. 11 (2004) 215-226
24. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 (2002) 991-998
25. Smyth M.J., Godfrey D.I., and Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2 (2001) 293-299
26. van Elsas A., Hurwitz A.A., and Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190 (1999) 355-366
27. Sun Y., Chen J.H., and Fu Y. Immunotherapy with agonistic anti-CD137: two sides of a coin. Cell Mol. Immunol. 1 (2004) 31-36
28. Melero I., Johnston J.V., Shufford W.W., Mittler R.S., and Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunol. 190 (1998) 167-172
29. Zhu Y., Zhu G., Luo L., Flies A.S., and Chen L. CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 109 11 (2007) 4882
30. Hendriks J., Xiao Y., Rossen J.W., van der Sluijs K.F., Sugamura K., Ishii N., and Borst J. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J. Immunol. 175 (2005) 1665-1676
31. Miescher S., Whiteside T.L., de Tribolet N., and von Fliedner V. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J. Neurosurg. 68 (1988) 438-448
32. Miller R.E., Jones J., Le T., Whitmore J., Boiani N., Gliniak B., and Lynch D.H. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol. 169 (2002) 1792-1800
33. Wilcox R.A., Flies D.B., Zhu G., Johnson A.J., Tamada K., Chapoval A.I., Strome S.E., Pease L.R., and Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109 (2002) 651-659
34. Kim J.A., Averbook B.J., Chambers K., Rothchild K., Kjaergaard J., Papay R., and Shu S. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res. 61 (2001) 2031-2037
35. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., Davis T., Henry-Spires R., MacRae S., Willman A., Padera R., Jaklitsch M.T., Shankar S., Chen T.C., Korman A., Allison J.P., and Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4712-4717
36. Korman A.J., Peggs K.S., and Allison J.P. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90 (2006) 297-339
37. Quezada S.A., Peggs K.S., Curran M.A., and Allison J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116 (2006) 1935-1945
38. Hurwitz A.A., Foster B.A., Kwon E.D., Truong T., Choi E.M., Greenberg N.M., Burg M.B., and Allison J.P. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60 (2000) 2444-2448
39. Sato T., Terai M., Yasuda R., Watanabe R., Berd D., Mastrangelo M.J., and Hasumi K. Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy. Cancer Immunol. Immunother. 53 (2004) 53-61
40. Gri G., Gallo E., Di Carlo E., Musiani P., and Colombo M.P. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J. Immunol. 170 (2003) 99-106